Learn about the latest treatments for advanced esophageal cancer. We’ve got it covered, from new FDA approvals to emerging approaches in immunotherapy, targeted therapy, drug combinations, and more.

  • July 28, 2021  

    2021 ASCO Annual Meeting Bookmark

    George Lundberg, MD

    Researchers at the 2021 annual meeting of the American Society of Clinical Oncology (ASCO) reported substantial advances in treatment for advanced esophageal, castration-resistant prostate, and metastatic nasopharyngeal cancers.

    .

  • December 3, 2020  

    A Phase I Study of Telomelysin Added to Chemoradiation for Patients with Advanced Inoperable Esophageal Cancer Bookmark

    George Lundberg, MD

    Memorial Sloan Kettering Cancer Center recently began recruiting patients for a phase 1 clinical trial to test a treatment in which an investigational cancer cell-killing virus called Telomelysin is directly injected into inoperable esophageal cancer tumors. Participating patients will receive this “cancer vaccine” alongside standard chemoradiation therapy.

    .

    • SEE ALL
The team at Cancer Commons created a very thorough and clear report which is extremely helpful! It is evident they took the time to read my father’s medical history and suggest a personalized plan for his condition. Matt was extremely kind and supportive during this difficult time. Thank you!

Gali
Daughter of a glioblastoma patient

Molecular tests help match patients to the personalized treatments that are most likely to work for them. Keep up with new developments in genetic tests, tumor mutations, MSI status, other biomarkers, and additional precision-medicine strategies.

Some of the most promising new treatments for advanced esophageal cancer are currently being tested in patients enrolled in clinical trials. We help you stay up to date on the latest results from these studies.

  • April 12, 2021  

    Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer Bookmark

    George Lundberg, MD

    An academic research paper published in The New England Journal of Medicine reports new results from a phase III, randomized, double-blinded, controlled clinical trial. In the trial, people with esophageal or gastroesophageal junction cancer that had been surgically resected were treated with either a placebo drug or the drug nivolumab. All patients had previously received chemotherapy before resection and had residual disease after surgery. The findings suggest that nivolumab may be beneficial, as median disease-free survival in was doubled (22 versus 11 months) in the nivolumab treated group compared to the placebo group.

    .

  • November 24, 2020  

    For Esophageal Cancer, Immunotherapy Likely to Play Larger Role Bookmark

    George Lundberg, MD

    A blog post from the National Cancer Institute reports that two clinical trials are showing encouraging results for progression-free survival—and one for overall survival—from treatment with immunotherapy drugs in people with advanced esophageal cancer. 

    .

    • SEE ALL
Now is the time to be very actively involved in your own care.

Tony Blau, MD
University of Washington

Cancer affects many aspects of life, whether you’re newly diagnosed, in the midst of treatment, or in follow-up care. Learn about ways to maintain quality of life, such as palliative care and managing side effects.

  • August 11, 2021  

    Anxiety Before Each Chemotherapy Treatment Bookmark

    Lola Rahib, PhD

    Article from Let’s Win! Pancreatic Cancer: Pancreatic cancer patients share their experiences with pre-chemo anxiety and their personal strategies for overcoming it.

    .

  • February 11, 2020  

    ‘Impressed With Impact’ of Ketamine in Cancer Palliative Care Bookmark

    George Lundberg, MD

    Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

    Depression is, for obvious reasons, common in patients with advanced cancer. The old, inexpensive drug ketamine—already approved for medical use by the U.S. Food and Drug Administration (FDA)—seems rapidly effective, according to small studies.

    Go to full article published by Medscape.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

    • SEE ALL

You’re not alone. Read how other patients and caregivers navigated diagnosis, treatment, and life with cancer. We hope their stories provide insights and hope for your own cancer journey.

More patient stories

Learn more about what’s new in advanced cancer research and treatment, including screening and statistics, using artificial intelligence to improve treatment, and other new horizons in cancer care.

  • May 30, 2021  

    Cancer Support for LGBTQIA Patients Is Missing Bookmark

    George Lundberg, MD

    This piece from ASCO Connection outlines the need for and a path to improvement in cancer care for LGBTQIA patients.

    .

  • April 7, 2021  

    Rankings of Most Common and Deadly Cancer Types Will Shift Over Next Two Decades

    In the next two decades, rankings of incidence and death across cancer types will undergo important changes in the U.S., according to new research led by Lola Rahib, PhD, Director of Scientific and Clinical Affairs at Cancer Commons, as well as the Pancreatic Cancer Action Network (PanCAN) in collaboration with The University of Texas MD Anderson Cancer Center. Published today in JAMA Network Open,… Read more »

    • SEE ALL

The coronavirus pandemic presents unprecedented challenges to cancer patients. We can help you understand how COVID-19 might impact your treatment and other aspects of your cancer care.